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CD40 molecule is a 48 κDa protein that belongs 
to the superfamily of TNF receptors which contains 
a various number of cysteine rich domains as a charac-
teristic pattern [1–3]. First, CD40 molecule was found 
on bladder cancer cells, and later — on normal and 
transformed B-lymphocytes [4, 5]. Also CD40 may be 
expressed by other antigen-presenting cells (dendritic 
cells, macrophages), endothelial, epithelial, and neural 
cells, keratinocytes, fibroblasts, CD34+ hemopoietic 
precursor cells, as well by cells of tumors of different his-
togenesis and localization (tumors of mammary gland, 
intestine, stomach, nasopharynx, melanoma etc) [2, 6, 
7]. CD40L, a 39 kD ligand of CD40, known as CD154 or 
gp39, is mainly expressed by T-lymphocytes [2, 8].
CD40 molecule plays a central role in immunoregu-
lation and influences cell proliferation, activation and 
survival [9–11]. Interaction of CD40 and CD40L results 
in wide spectrum of effects on cells of immune system 
and on tumor cells. CD40 activation on tumor cells 
may alter tumor growth, in some cases leads to tumor 
growth inhibition, and in some cases — to growth 
stimulation or doesn’t influence it at all [11–13].
Involvement of CD40 in antitumor defense may 
occur via involvement of different mechanisms: promo-
tion of recognition by dendritic cells, induction of spe-
cific immunologic response with participation of В- and 
Т-lymphocytes, stimulation of cytotoxic Т-lymphocytes, 
natural killer cells, memory Т-cells, production of various 
cytokines (GM-CSF, IL-1, IL-4, IL-6, IL-8, IL-10, IL-12, 
RANTES and TNFα), elevation of expression of costimu-
latory molecules on tumor cell surface, etc [14–17].
As has been shown in the studies of solid tumors 
and some lymphoproliferative diseases, CD40/CD40L 
interaction plays an important role in induction of 
apoptosis [12, 15].
Along with possibility of tumor cells death due to 
their interaction with Т-lymphocytes expressing CD40L, 
such interaction may lead as well to accelerated tu-
mor growth, which could be realized via numerous 
mechanisms: production of cytokines promoting tumor 
growth, in particular, secretion of angiogenic cytokines; 
promotion of adhesive properties etc. [13, 18].
The data of a number of authors have demon-
strated that CD40 expression may be accompanied by 
the development of multiple drug resistance (to doxo-
rubicine, vinblastin etc) by caspase-independent and 
caspase-dependent pathways [12, 19]. As we have 
shown earlier, the tumors resistant even to a single 
antitumor drug possess elevated sensitivity to the 
action of cytotoxic cells, in particular, when activated 
by IL-2, in vitro and in vivo [20].
The aim of the present study was to perform a com-
parative evaluation of the efficacy of antitumor action of 
lymphocytes against chemoresistant and chemosen-
sitive breast tumors dependent on CD40 expression, 
and to analize the rate of CD40 expression by the cells 
of benign and malignant tumors of mammary gland. To 
find a possible relation between CD40 expression and 
antitumor action of lymphocytes, it was interestingly to 
study possible association between such action and 
the level of proliferative and adhesive activity of tumor 
cells and lymphocytes. 
MATERIALS AND METHODS
Tumor tissue samples and PBL were obtained 
from the patients with benign (n = 12; diagnosis — 
fibro adenoma, fibrocystoma mastopathy, fibroade-
nomatosis, macromastia) and malignant (n = 8; dia-
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gnosis — breast carcinoma) breast tumors cured in 
the Department of Surgery of Kyiv Hospital № 1 (Kyiv, 
Ukraine). The studies were carried out in accordance 
to the International and State rules on Bioethics.
Tumor explants (the slices of tumor tissue < 0.2 mm3 ob-
tained during surgical treatment) were studied. Lympho-
cytes were isolated from whole heparinized blood by 
centrifugation in the ficoll-verografin density gradient. 
Individual sensitivity of tumor explants to antitumor drugs 
(doxorubicine (Ebeve, Austria) — 0.02 mg/ml, cyclophos-
phane (Olanpharm, Latvia), 5-fluorouracil (Ebeve, Aus-
tria) — 0.006 mg/ml, methotrexate (Teva Pharmaceutical 
Industries LTD, Israel) — 0.005 mg/ml) was determined 
by cultivation of explants in diffusion chambers in culture 
medium supplemented with mentioned drugs. 
To produce lymphokine activated killer cells (LAK), 
lymphocytes were incubated with RIL-2 (1000 MU/ml) 
(BIOTECH, Russia) for 2 h at 37 °С in 5% СО2, and 
twice washed.
Antitumor activity of lymphocytes has been ana-
lyzed by the patterns of tumor explants growth upon 
their co-cultivation in diffusion chambers. Tumor cells 
and lymphocytes were co-cultivated for 5 days in 
complete RPMI-1640 medium (Sigma, USA) at 37 °С 
in atmosphere of 5% СО2. Then the filters of diffusion 
chambers were fixed, stained by Karacchi hematoxy-
lin, treated by spirits (50°, 70°, 96°, 100°) and xylene, 
and preparations for microscopic examination were 
prepared using canadian balsam.
The evaluation of PBL and LAK antitumor activity 
was done based on morphological patterns of explant’s 
growth: destruction of tumor cells, the absence of tumor 
cell migration from explant, migration of single tumor 
cells from explant, formation of monolayer of different 
density; formation of cell conglomerates; formation of 
spheroids [20].
Expression of CD40, p53 and antigen of proliferating 
cells IPO-38 by tumor tissue samples or PBL of the pa-
tients was determined with the use of respective mono-
clonal antibodies (mAbs) (IEPOR NASU). Anti-CD40 mAb 
were kindly provided by Dr. Edward A.Clark (University of 
Washington, Department of Immunology, Seattle, USA). 
mAbs were used at the concentration of 40 µg/ml. To de-
termine the expression of mentioned proteins on tumor 
tissue, surgically resected tissue samples were fixed in 
formalin, and after standard histological treatment were 
placed in paraffin blocks. For immunohistochemical 
study, the 4–5 µm slides were treated with the respective 
mAbs and secondary complex EnVision (DAKO, Den-
mark). The level of protein expression was evaluated by 
semiquantative method (by the sum of scores for stained 
cells and by intensity staining) (Table 1) [21].
To determine the expression of CD40, CD54 and 
nuclear antigen of proliferating cells by PBL, the method 
of indirect immunofluorescence was used: the cells were 
stained by mentioned mAb, than incubated with secon-
dary rabbit FITC-conjugated anti-mouse IgG antibodies 
(Sigma, USA). For detection of antigen of proliferating 
cells, lymphocytes were fixed for 5 min in 3.7% para-
formaldeghyde solution (Sigma, USA), then treated with 
0.2% Triton X-100 (Sigma, USA). After that the reaction 
was performed similarly to that for surface antigens. For 
the study, LUMAM-1 microscope was used. The percent 
of cells that bound fluorescence probe, was calculated.
Table 1. Semiquantative evaluation of immunohistochemical detection of 
the molecules (by Allred D.C.) 
1. The part of positively stained cells Score
0 0
1–10 1
10–30 2
30–45 3
45–60 4
60–100 5
2. Staining intensity
Negative 0
Low 1
Median 2
High 3
3. Total score
Note. The level of proteins expression of was evaluated by the sum of scores 
for stained cells and by intensity of the staining [21].
Statistical analysis of the data was performed with 
the use of the methods of variation statistics.
RESULTS AND DISCUSSION
In our study of the expression of CD40, CD54 and 
nuclear antigen of proliferating cells IPO-38 by drug 
resistant (n = 6) and drug sensitive (n = 2) malignant 
and benign breast tumors it was shown that the highest 
expression level of CD40 was present on chemoresis-
tant tumor cells, while the lowest one — on the cells of 
benign tumors. It has been also recorded that there is 
an elevation of IPO-38 and p53 expression in the cells 
of drug resistant tumors compared with drug sensitive 
ones. Their lowest expression level was observed in the 
cells of benign tumors (Tables 2 and 3, Figs.1, 2).
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Fig. 1. Expression of CD40, р53 and antigen of proliferating cells by 
benign and malignant breast tumor cells resistant or sensitive to anti-
tumor drugs. *Reliable difference between p53 and CD40 expression 
by tumor cells of malignant and benign tumors (P < 0.5).
Fig. 2. Expression of CD40 by drug resistant breast cancer tumor 
cells, × 200
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Table 2. Expression of CD40, p53 and antigen of proliferating cells (IPO-38) 
by drug resistant breast carcinoma cells (immunohistochemical scores)
Case 
number Diagnosis
Sensitivity to the 
action of drugs
Expression, score
CD40 IPO-38 p53
1 Resistant 
carcinoma
Doxorubicine
Metotrexate
8 7 8
2 Resistant 
carcinoma
Cyclophosphane
Metotrexate
5-fluorouracil
7 6 8
3 Resistant 
carcinoma
Doxorubicine
Cyclophosphane
Methotrexate
7 3 7
4 Resistant 
carcinoma
Doxorubicine
Metotrexate
6 7 7
5 Resistant 
carcinoma
Cyclophosphane
Metotrexate
5-fluorouracil
5 7 6
6 Resistant 
carcinoma
Doxorubicine
Metotrexate
5-fluorouracil
7 6 7
Note. Score — semiquantitive evaluation by Allred D.C.
Table 3. Expression of CD40, p53 and antigen of proliferating cells 
(IPO-38) by cells of benign breast tumors (immunohistochemical scores)
Case 
number Diagnosis
Еxpression, score
CD40 IPO-38 p53
1 Fibroadenoma 6 6 5
2 Fibroadenoma 5 3 3
3 Fibroadenoma 6 5 3
4 Phyloid fibroadenoma 7 5 2
5 Fibroadenoma 5 6 4
6 Fibroadenoma 6 4 4
7 Fibroadenoma 4 3 3
8 Focalfibroadenomatosis 4 5 0
9 Cyclomastopathy 2 3 3
10 Cyclomastopathy 3 3 3
11 Papilloma with ulcerations 2 4 2
12 Macromastia 3 5 3
Note. Score — semiquantitive evaluation by Allred D.C.
The level of CD40, CD54 and antigen of prolifera-
ting cells was studied in parallel on PBLs from breast 
cancer patients. We have shown that CD40 and 
IPO-38 expression by PBLs from the patients with drug 
resistant breast cancer was decreased, CD54 expres-
sion was elevated compared with these indexes in the 
case of drug sensitive breast tumors. The levels of 
CD40 and IPO-38 expression by PBLs of patients with 
benign tumors were significantly higher than those in 
patients with malignant tumors (Tables 4, 5). 
The study of antitumor activity of non-activated and 
IL-2-activated PBLs showed that LAK from the patients 
with drug resistant breast cancer were active in the 
majori ty of cases: such activity manifested itself by an 
absence of tumor cell migration from explants or migra-
tion of single cells. In the control, only migration of cells 
from explant and formation of monolayer of low or me-
dium density was observed. Non-activated lymphocytes 
from patients with drug resistant tumors in the majority of 
cases possessed weak antitumor activity (Table 6). 
Table 4. Expression of CD40, CD54 and antigen of proliferating cells 
(IPO-38) by PBLs from patients with drug resistant malignant breast tumors 
(immunofluorescence)
Case 
number Diagnosis
Expression, %
CD40 IPO-38 CD54
1 Resistant carcinoma 4 5 18
2 Resistant carcinoma 10 3 10
3 Resistant carcinoma 6 5 8
4 Resistant carcinoma 5 6 15
5 Resistant carcinoma 5 7 8
6 Resistant carcinoma 6 3 8
Note. % — percent of positive cells.
Table 5. Expression of CD40, CD54 and antigen of proliferating cells (IPO-38) 
by PBLs from the patients with benign breast tumors (immunofluorescence)
Case 
number Diagnosis
Expression, %
CD40 IPO-38 CD54
1 Fibroadenoma 6 15 14
2 Fibroadenoma 11 9 10
3 Fibroadenoma 10 15 4
4 Phyloid fibroadenoma 12 10 5
5 Fibroadenoma 10 6 10
6 Fibroadenoma 10 5 10
7 Fibroadenoma 5 5 8
8 Focalfibroadenomatosis 5 5 15
9 Cyclomastopathy 12 8 14
10 Cyclomastopathy 10 5 5
11 Papilloma with ulcerations 10 5 10
12 Macromastia 4 7 10
Note. % — percent of positive cells.
In contrary, non-activated and activated by IL-2 PBLs 
from the patients with benign tumors in the majority of 
cases did not possess antitumor activity: tumor growth 
pattern practically did not differ from the control.
Drug resistant tumor cells demonstrated elevated 
sensitivity to the LAK action. The obtained results showed 
that the pronounced antitumor activity of LAK was associ-
ated with high expression level of CD40, р53 and antigen 
of proliferating cells (IPO-38) by tumor cells, while on 
patients’ PBLs decreased expression of CD40 and IPO-
38 and increased CD54 expression were detected.
So, we addressed the questions: what mechanisms 
caused such elevated sensitivity of drug resistant tumors 
to the applied adoptive immunotherapy approach, and 
what are the possible ways of CD40 impact on antitumor 
activity of lymphocytes. Unfortunately, the respective 
data are scarce, but according to the literature data, IL-2-
activated lymphocytes acquire some properties favoring 
active lysis of target cells: elevation of adhesion molecules 
expression, promotion of lymphocytes interaction with 
tumor cells, synthesis and secretion of different cytokines 
by LAK, etc [22–25]. We demonstrated that the highest 
expression level of CD54 (ICAM-1) was observed on 
lymphocytes from the patients with drug resistant breast 
cancer. It could be suggested that among the factors 
influencing elevated sensitivity of LAK to drug resistant 
tumors, high expression level of adhesion molecules could 
be important. During the development of drug resistance, 
Table 6. Sensitivity of breast carcinoma explants to antitumor activity of PBL and LAK (morphological patterns of explants growth)
Case 
number Diagnosis
Antitumor activity of lymphocytes
Growth of explantats (control) Action of PBL Action of LAK
1 Resistant carcinoma Monolayer of medium density Monolayer of low density No migration
2 Resistant carcinoma Monolayer of medium density Monolayer of low density Monolayer of low density
3 Resistant carcinoma Migration of single cells Migration of single cells No migration; destruction
4 Resistant carcinoma Monolayer of medium density No migration No migration
5 Resistant carcinoma Monolayer of medium density Monolayer of medium density Initial stage of monolayer formation
6 Resistant carcinoma Monolayer of low density Initial stage of monolayer formation Migration of single cells
7 Fibroadenoma with microcalcification 
(carcinoma in situ); chemosensitive
Migration of single cells Migration of single cells No migration
8 Chemosensitive carcinoma  Monolayer of medium density No migration No migration; destruction
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elevated sensitivity to the LAK action may be also caused 
by such factors as altered expression of some membrane 
proteins on tumor cells, for example, Р-gp, production of 
ATP by tumor cells (promoting LAK cytotoxicity, changing 
tumor cell adhesive properties, etc) [26–28].
Induction of apoptosis in different types of tumor 
cells is one of the main mechanisms of CD40 inhibit-
ing influence on tumor growth [5, 29]. This statement 
is supported by the fact that upon CD40 activation, 
expression of FasL, TRAIL (Apo-2L), Fas and ICAM-1 on 
tumor cell surface and expression of cytokines IL-1, 
IL-6, IL-8, IL-10, IL-12, GM-CSF, TNFα is observed [17, 
30]. Despite the fact that the death domain is absent in 
С-terminus of CD40 molecule, the ability of this mole-
cule to transfer death signals to the nucleus is realized 
via adapter proteins of TRAF family (TNF Receptor-
Associated Factor), TRAF2 and TRAF6 [29, 31]. 
The basic mechanism of tumor growth suppression 
upon CD40 up-regulation is stimulation of immune 
system cells, involved in antitumor defense. In par-
ticular, CD40 promotes antigen-presenting functions 
of dendritic cells, macrophages, monocytes, and 
production of cytokines (IFNγ, IL-12). This increases 
cytotoxicity of macrophages and dendritic cells, and 
induces expression of antiapoptotic Bcl-2 protein by 
dendritic cells, as well as antibody-dependent cyto-
toxicity of natural killer cells, cytotoxic Т-lymphocytes 
and memory Т-cells [12, 17, 32]. 
Expression of CD40 by В-lymphocytes favors their 
enhanced proliferation, differentiation, expression of 
co-stimulatory molecules and antigen presentation 
[33]. As a result of В lymphocytes activation, induction 
of antitumor T-cell response occurs due to the direct 
influence on В lymphocytes and indirect influence on 
other antigen presenting cells [12].
In conclusion, we suggest that the increased sen-
sitivity of drug resistant breast tumor cells expressing 
CD40 to the LAK action may be mediated by expres-
sion of adhesion molecules in parallel with activation 
of cytotoxic cells, and possibly — by apoptotic mecha-
nisms. However, this problem requires further studies. 
The conclusions are grounded on uniformity of the 
data obtained in the study of samples of drug resistant 
tumors and their comparison with large control group 
of the patients with benign tumors (n = 12).
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ЭКСПРЕССИЯ CD40 КЛЕТКАМИ ДОБРОКАЧЕСТВЕННЫХ 
И ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ МОЛОЧНОЙ ЖЕЛЕЗЫ 
И ПРОТИВООПУХОЛЕВОЕ ДЕЙСТВИЕ LAK В ОТНОШЕНИИ 
ХИМИОРЕЗИСТЕНТНЫХ И ЧУВСТВИТЕЛЬНЫХ ОПУХОЛЕЙ
Цель: изучение частоты экспрессии CD40 клетками злокачественных и доброкачественных опухолей молочной железы и срав-
нение эффективности противоопухолевого действия лимфоцитов в зависимости от экспрессии CD40 в отношении резистентных 
и чувствительных опухолей молочной железы. Методы: культивирование эксплантатов опухолей молочной железы с ауто-
логичными лимфоцитами в двойных диффузионных камерах. Оценку результатов проводили на основании морфологических 
критериев роста эксплантатов. Для определения экспрессии молекул на опухолевых клетках использовался иммуногистохи-
мический метод (парафиновые срезы), а на лимфоцитах — метод непрямой иммунофлуоресценции. Результаты: наиболее 
высокий уровень экспрессии молекул CD40 отмечен на клетках резистентных злокачественных опухолей молочной железы по 
сравнению с опухолями, чувствительными к химиопрепаратам, а наиболее низкий — на клетках доброкачественных опухолей. 
Установлено снижение экспрессии CD40 лимфоцитами больных со злокачественными резистентными опухолями молочной 
железы по сравнению с лимфоцитами больных с чувствительными опухолями. На лимфоцитах больных с доброкачественными 
опухолями уровень экспрессии CD40 был значительно выше по сравнению со злокачественными. Изучение противоопухолевой 
активности аутологичных ЛАК показало, что противоопухолевое действие у больных со злокачественными опухолями, резис-
тентными к химиопрепаратам, было более выражено. Выводы: выраженная противоопухолевая активность ЛАК больных со 
злокачественными опухолями, резистентными к химиопрепаратам, ассоциируется с высоким уровнем экспрессии CD40 на 
опухолевых клетках и со снижением его экспрессии на лимфоцитах. 
Ключевые слова: CD40, p53, CD54, пролиферация клеток, доброкачественные и злокачественные опухоли молочной 
железы, химиорезистентность, ЛАК.
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